Posted by Marilyn Orr on Apr 11, 2018

Pledge and Invocation

President Mike called the meeting to order.  He asked Alex Buljan to lead us in the Pledge of Allegiance even though the flag seemed to be missing or obscured.  Paul Watermulder then provided the invocation for the lunch and meeting.
Visiting Rotarians & Guests: Visiting Rotarian Suni Arora of the San Mateo Club joined us.  Also in attendance was former Burlingame Rotarian Ken Housley.  Former member Phillip Larson partook of the meeting and meal, as well.


Cheri Delacy-Carr reminded us again to purchase our tickets for Burlingame Bistro on Sunday, May 20th.  You can do so through ClubRunner or by giving your check or credit card to Marilyn Orr.  Tickets are $100.  She gave a shout-out to the board members who have pledged to become Benefactor sponsors for $500.  This entitles them to two tickets plus recognition at the event and in the program.  Jennifer Pence then made a plea for auction items for this event.  So ask your favorite restaurant, haircutter, nail salon, etc for gift certificates.  The NEWSCAST was back! Cheri entertained us with examples of haircuts.


Member Wendy Upchurch introduced our speaker, her husband David Upchurch.  David is currently with Jaguar Health but has been in the pharmaceutical industry for over 25 years.  He spent 15 years with Gilead Sciences. His topic, “Putting the Pill in the Bottle”, took us through the lengthy and complicated development of a drug from discovery and concept to the shelf of your local pharmacy.  David explained the stages beginning with basic drug discovery into pre-clinical development and toxicology testing.  At this point it can be presented to the FDA for an initial drug approval.  Once accepted the process then moves to vigorous phases of testing.  Phase I testing is done in healthy human volunteers to insure the drug “does no harm”.   Phase II tests its efficacy with a larger sample of volunteers.  In Phase III the new drug goes up against a placebo to demonstrate its superiority.  The process to this point can take anywhere from 2 to 5 years.  If these are all successful the developer goes back to the FDA with their NDA (New Drug Application) which can take from 3 to 24 months for approval.  Then comes the final launch.  But this is no picnic.  In this highly regulated industry there is a specific process, much of it outlined both in the NDA and regulations, related to packaging, shelf life, distribution, traceability, temperature and anti-counterfeit protocols.  David showed us some of the sophisticated equipment necessary for creating the tablets.  If all goes well your local CVS will finally have this new drug on its shelves.  Thank you David for giving us a new appreciation of what goes into creating the next “miracle” drug.